These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

334 related items for PubMed ID: 18763216

  • 1. Drug discovery and development for Huntington's disease - an orphan indication with high medical need.
    Heitz F, La Rosa S, Gonzalez-Couto E, Gaviraghi G, Terstappen GC.
    IDrugs; 2008 Sep; 11(9):653-60. PubMed ID: 18763216
    [Abstract] [Full Text] [Related]

  • 2. Emerging drug therapies in Huntington's disease.
    Mason SL, Barker RA.
    Expert Opin Emerg Drugs; 2009 Jun; 14(2):273-97. PubMed ID: 19453283
    [Abstract] [Full Text] [Related]

  • 3. Investigational agents for the management of Huntington's disease.
    Müller T.
    Expert Opin Investig Drugs; 2017 Feb; 26(2):175-185. PubMed ID: 27927041
    [Abstract] [Full Text] [Related]

  • 4. Investigational drugs for the management of Huntington's disease: are we there yet?
    Kulkarni P, Saxena U.
    Expert Opin Investig Drugs; 2014 Dec; 23(12):1595-603. PubMed ID: 25084527
    [Abstract] [Full Text] [Related]

  • 5. Translation of rare disease research into orphan drug development: disease matters.
    Heemstra HE, van Weely S, Büller HA, Leufkens HG, de Vrueh RL.
    Drug Discov Today; 2009 Dec; 14(23-24):1166-73. PubMed ID: 19818412
    [Abstract] [Full Text] [Related]

  • 6. Valproate ameliorates the survival and the motor performance in a transgenic mouse model of Huntington's disease.
    Zádori D, Geisz A, Vámos E, Vécsei L, Klivényi P.
    Pharmacol Biochem Behav; 2009 Nov; 94(1):148-53. PubMed ID: 19698736
    [Abstract] [Full Text] [Related]

  • 7. Pharmacologic approaches to the treatment of Huntington's disease.
    Venuto CS, McGarry A, Ma Q, Kieburtz K.
    Mov Disord; 2012 Jan; 27(1):31-41. PubMed ID: 21997232
    [Abstract] [Full Text] [Related]

  • 8. Therapeutic options for Huntington's disease.
    Grimbergen YA, Roos RA.
    Curr Opin Investig Drugs; 2003 Jan; 4(1):51-4. PubMed ID: 12625029
    [Abstract] [Full Text] [Related]

  • 9. Regulatory considerations for developing drugs for rare diseases: orphan designations and early phase clinical trials.
    Pariser AR, Xu K, Milto J, Coté TR.
    Discov Med; 2011 Apr; 11(59):367-75. PubMed ID: 21524390
    [Abstract] [Full Text] [Related]

  • 10. Drugs for rare diseases: mixed assessment in Europe.
    Prescrire Int; 2007 Feb; 16(87):36-42. PubMed ID: 17323539
    [Abstract] [Full Text] [Related]

  • 11. Huntington's disease: which drugs might help patients?
    Hannan AJ.
    IDrugs; 2004 Apr; 7(4):351-8. PubMed ID: 15057641
    [Abstract] [Full Text] [Related]

  • 12. Protective effect of rivastigmine against 3-nitropropionic acid-induced Huntington's disease like symptoms: possible behavioural, biochemical and cellular alterations.
    Kumar P, Kumar A.
    Eur J Pharmacol; 2009 Aug 01; 615(1-3):91-101. PubMed ID: 19445928
    [Abstract] [Full Text] [Related]

  • 13. Emerging chemotherapeutic strategies for Huntington's disease.
    Ryu H, Ferrante RJ.
    Expert Opin Emerg Drugs; 2005 May 01; 10(2):345-63. PubMed ID: 15934871
    [Abstract] [Full Text] [Related]

  • 14. Clinical utility of neuroprotective agents in neurodegenerative diseases: current status of drug development for Alzheimer's, Parkinson's and Huntington's diseases, and amyotrophic lateral sclerosis.
    Dunkel P, Chai CL, Sperlágh B, Huleatt PB, Mátyus P.
    Expert Opin Investig Drugs; 2012 Sep 01; 21(9):1267-308. PubMed ID: 22741814
    [Abstract] [Full Text] [Related]

  • 15. Androgen function in the pathophysiology and treatment of male Huntington's disease patients.
    Ransome MI.
    J Neuroendocrinol; 2012 Oct 01; 24(10):1275-83. PubMed ID: 22672384
    [Abstract] [Full Text] [Related]

  • 16. A controlled clinical trial of baclofen as protective therapy in early Huntington's disease.
    Shoulson I, Odoroff C, Oakes D, Behr J, Goldblatt D, Caine E, Kennedy J, Miller C, Bamford K, Rubin A.
    Ann Neurol; 1989 Mar 01; 25(3):252-9. PubMed ID: 2524992
    [Abstract] [Full Text] [Related]

  • 17. European Medicines Agency support mechanisms fostering orphan drug development.
    Butlen-Ducuing F, Rivière F, Aarum S, Llinares-Garcia J.
    Drug News Perspect; 2010 Mar 01; 23(1):71-81. PubMed ID: 20155221
    [Abstract] [Full Text] [Related]

  • 18. The R6 lines of transgenic mice: a model for screening new therapies for Huntington's disease.
    Gil JM, Rego AC.
    Brain Res Rev; 2009 Mar 01; 59(2):410-31. PubMed ID: 19118572
    [Abstract] [Full Text] [Related]

  • 19. Developing treatments for inborn errors: incentives available to the clinician.
    Haffner ME.
    Mol Genet Metab; 2004 Apr 01; 81 Suppl 1():S63-6. PubMed ID: 15050976
    [Abstract] [Full Text] [Related]

  • 20. Yeast as a drug discovery platform in Huntington's and Parkinson's diseases.
    Outeiro TF, Giorgini F.
    Biotechnol J; 2006 Mar 01; 1(3):258-69. PubMed ID: 16897706
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.